Trial Profile
An Extension Study of CACZ885N2301 (NCT02059291), Multi-center, Open Label Study of Canakinumab in Japanese Patients With Periodic Fever Syndromes (Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS), Hyper Immunoglobulin D Syndrome ((Also Known as Mevalonate Kinase Deficiency) (HIDS/MKD), or Colchicine Resistant/Intolerant Familial Mediterranean Fever (crFMF))
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 27 Aug 2018
Price :
$35
*
At a glance
- Drugs Canakinumab (Primary)
- Indications Hereditary autoinflammatory diseases
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 04 May 2017 Status changed from active, no longer recruiting to completed.
- 13 Dec 2016 Status changed from recruiting to active, no longer recruiting.
- 29 Sep 2016 New trial record